TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of Approval

TNT-119 is under clinical development by Eliem Therapeutics and currently in Phase I for Membranous Glomerulonephritis.

AI’s potential to improve healthcare access could be offset by exploitation

As tools powered by artificial intelligence increasingly make their way into health care, the latest research from UC Santa Cruz Politics Department doctoral candidate Lucia

October 9, 2024

UPenn sues BioNTech, says it owes ‘significant’ Covid-related royalties

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 8, 2024

Signal: NHS whistle-blower policy questioned following Letby conviction – Pharmaceutical Technology

Numerous doctors at the Countess of Chester Hospital raised concerns about Letby, but were ignored. Credit: Christopher Furlong / Getty Images. Following the conviction of

August 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.